Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan

被引：0
|
作者：
Gonzalez-Baron, M. [1 ]
Blanco, M. [1 ]
Feliu, J. [1 ]
Gomez, C. [1 ]
Casado, E. [1 ]
Castro, J. [1 ]
Belda-Iniesta, C. [1 ]
Garrido, M. [1 ]
Aguayo, C. [1 ]
Campos, M. A. [1 ]
机构：
[1] Hosp La Paz, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14600
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.
    Lenz, HJ
    Mayer, RJ
    Gold, PJ
    Mirtsching, B
    Stella, PJ
    Cohn, AL
    Pippas, AW
    Azarnia, N
    Needle, MN
    Van Cutsem, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 247S - 247S
  • [2] Cetuximab plus irinotecan in refractory colorectal cancer patients
    Delgao, Marian Gil
    Spano, Jean-Philippe
    Khayat, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 407 - 413
  • [3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04): : 337 - 345
  • [4] Cetuximab and irinotecan in patients with EGFR plus colorectal cancer refactory to oxaliplatin and irinotecan: A single institution experience
    Herrero, A
    Alonso, V
    Lao, J
    de Lobera, AR
    Pazo, R
    Martinez-Trufero, J
    Puertolas, T
    Calderero, V
    Artal, A
    Anton, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 302S - 302S
  • [5] Cetuximab alone or in combination with irinotecan effective against irinotecan refractory colorectal cancer
    Lang, L
    GASTROENTEROLOGY, 2004, 127 (03) : 701 - 701
  • [6] Therapy with cetuximab and irinotecan in refractory metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (9): : 497 - 498
  • [7] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [8] MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
    Bernard Paule
    Vincent Castagne
    Véronique Picard
    Raphaël Saffroy
    René Adam
    Catherine Guettier
    Robert Farinotti
    Laurence Bonhomme-Faivre
    Medical Oncology, 2010, 27 : 1066 - 1072
  • [9] MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
    Paule, Bernard
    Castagne, Vincent
    Picard, Veronique
    Saffroy, Raphael
    Adam, Rene
    Guettier, Catherine
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    MEDICAL ONCOLOGY, 2010, 27 (04) : 1066 - 1072
  • [10] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
    Tahara, Makoto
    Shirao, Kuniaki
    Boku, Narikazu
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Inaba, Yoshitaka
    Arai, Tatsuhiro
    Mizunuma, Nobuyuki
    Satoh, Taroh
    Takiuchi, Hiroya
    Nishina, Tomohiro
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 762 - 769
12345